NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
Want to see NTHI full AI Analyst Report?
Top Page
NeOnc Technologies Holdings, Inc.
(NASDAQ:NTHI)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.00
▼(-43.69% Downside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by very weak financial performance (no TTM revenue, large losses, heavy cash burn, and negative equity). Technicals are only modestly supportive (near-term strength but longer-term downtrend), while valuation signals are constrained by losses (negative P/E). Corporate events add some upside from regulatory progress and funding actions, but they do not fully offset the underlying financial risk.
Positive Factors
UAE IND clearance for NEO212
UAE IND clearance establishes the first international regulatory pathway for NEO212, enabling trials outside the U.S. This diversifies regulatory risk, can accelerate patient enrollment and data generation, and creates an alternate route toward registrational evidence, reducing single-jurisdiction dependency.
Negative Factors
Zero TTM revenue; large cash burn
Zero trailing revenue combined with roughly -$21.7M TTM operating and free cash flow means NeOnc cannot self-fund operations. Persistent cash burn constrains strategic flexibility, forces prioritization of programs, and makes long-term continuity dependent on external capital availability.
Read all positive and negative factors
Positive Factors
Negative Factors
UAE IND clearance for NEO212
UAE IND clearance establishes the first international regulatory pathway for NEO212, enabling trials outside the U.S. This diversifies regulatory risk, can accelerate patient enrollment and data generation, and creates an alternate route toward registrational evidence, reducing single-jurisdiction dependency.
Read all positive factors
NeOnc Technologies Holdings, Inc. (NTHI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$137.09M
Dividend YieldN/A
Average Volume (3M)103.40K
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.94
Shares Outstanding26,013,136
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.01K
Enterprise Value/Ebitda-2.74
Forecast
1Y Price Target
$16.00Price Target Upside80.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model
Company Description
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently und...
NeOnc Technologies Holdings, Inc. Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| Gross Profit | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| EBITDA | -59.61M | -9.10M | -12.20M | -2.85M | -3.26M |
| Net Income | -62.15M | -11.90M | -14.92M | -3.05M | -3.38M |
Balance Sheet | |||||
| Total Assets | 2.82M | 3.42M | 1.27M | 728.68K | 32.49K |
| Cash, Cash Equivalents and Short-Term Investments | 58.73K | 64.89K | 31.86K | 633.30K | 25.03K |
| Total Debt | 6.31M | 24.72K | 6.61M | 50.00K | 1.15M |
| Total Liabilities | 20.33M | 8.92M | 15.25M | 2.30M | 2.65M |
| Stockholders Equity | -17.51M | -5.50M | -13.99M | -1.58M | -2.62M |
Cash Flow | |||||
| Free Cash Flow | -20.86M | -4.21M | -1.88M | -881.74K | -396.69K |
| Operating Cash Flow | -20.36M | -4.21M | -1.88M | -881.74K | -396.69K |
| Investing Cash Flow | -500.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 20.86M | 4.25M | 1.28M | 1.49M | 250.00K |
NeOnc Technologies Holdings, Inc. Risk Analysis
NeOnc Technologies Holdings, Inc. disclosed 83 risk factors in its most recent earnings report. NeOnc Technologies Holdings, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeOnc Technologies Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $137.09M | -3.18 | 284.28% | ― | ― | ― | |
47 Neutral | $18.54M | -0.33 | -356.99% | ― | ― | -152.00% | |
42 Neutral | $3.26M | -0.09 | ― | ― | ― | 76.55% | |
41 Neutral | $6.98M | -0.13 | -709.51% | ― | -84.76% | 79.01% |
* Healthcare Sector Average
NTHI
NeOnc Technologies Holdings, Inc.
5.27
0.79
17.63%
GOVX
GeoVax Labs
1.34
-20.53
-93.87%
GTBP
GT Biopharma
0.51
-2.70
-83.99%
CLDI
Calidi Biotherapeutics
0.17
-3.25
-95.09%
NeOnc Technologies Holdings, Inc. Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
NeOnc Wins UAE IND Clearance for NEO212 Brain Therapy
Positive
Jun 18, 2026
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company specializing in central nervous system cancers, is advancing a pipeline centered on overcoming the blood-brain barrier, notably through its NEO100 and NEO212 candidates ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NeOnc Technologies Announces New Series A Preferred Financing
Positive
Jun 12, 2026
On June 10, 2026, NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement with accredited investors to privately place up to $5 million of Series A Convertible Preferred Stock, authorizing 6,000 shares at $833.34 each, exemp...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
NeOnc Advances Glioma Programs and Strengthens Financial Position
Positive
May 18, 2026
In the first quarter of 2026, NeOnc Technologies Holdings, Inc. reported completing the Phase 1 dose-escalation study of NEO212 and setting 610 mg as the recommended Phase 2 dose, with early signs of efficacy in heavily pretreated recurrent gliobl...
Business Operations and StrategyPrivate Placements and Financing
NeOnc Raises Capital Through Private Equity Offerings
Positive
Apr 24, 2026
Between January 29 and April 20, 2026, NeOnc Technologies Holdings, Inc. executed a series of four securities purchase agreements to issue common stock and accompanying five-year warrants at per-share prices of $7.20 and $9.00, respectively. Acros...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
NeOnc CEO Increases Stake Amid Advancing CNS Cancer Programs
Positive
Apr 16, 2026
On April 14, 2026, NeOnc Technologies Holdings, Inc. reported that Chairman and CEO Amir Heshmatpour bought roughly $300,000 of company stock in the prior week, signaling management’s confidence as it approaches key milestones for its CNS ca...
Private Placements and FinancingRegulatory Filings and Compliance
NeOnc Technologies Launches $75 Million ATM Equity Program
Neutral
Apr 10, 2026
On April 10, 2026, NeOnc Technologies Holdings, Inc. entered into an Equity Distribution Agreement with BTIG, LLC and A.G.P./Alliance Global Partners to establish an at-the-market equity program allowing the company to sell up to $75 million of it...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
NeOnc Technologies Reports Q4 Results and Trial Progress
Neutral
Apr 3, 2026
NeOnc Technologies reported Q4 and full-year 2025 results on April 1, 2026, highlighting completion of the Phase 1 trial for NEO212 with a recommended Phase 2 dose of 610 mg and early signs of anti-tumor activity in recurrent glioblastoma and brai...
Business Operations and StrategyPrivate Placements and Financing
NeOnc Announces New Private Placement to Support Liquidity
Neutral
Mar 23, 2026
NeOnc Technologies Holdings, Inc. has been executing a series of private securities offerings since January 29, 2026, issuing common stock and five-year warrants at fixed prices of $7.20 and $9.00, respectively. The first Securities Purchase Agree...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.